Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial

Effect of Second-Line Chemotherapy in Elderly Patients with Non-Small Cell Lung Cancer

“…Second-line chemotherapy and third-line chemotherapy were administered in 45.5% and 16.2% of patients, respectively, who received first-line chemotherapy in the age ≥ 75 group in this study, which were lower in frequency compared with the age 70-74 group in this study and previous reports [10][11][12]19,20]. The possible cause of not moving on to next line of therapy in the age ≥ 75 group is that older patients had more adverse events during chemotherapy than younger patients [21].…”

“…ORR of the second-line chemotherapy was 9.2% [95% confidence interval (CI), [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] in age ≥ 75 group and 12.2% (95% CI, 5-26) in age 70-74 group. There was no significance difference between the groups (p=0.75).…”

Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung

“…22,26) Nedaplatin is a cisplatin derivative designed to reduce cisplatin toxicity and has potential antitumor effects against SCC in various organs. 10,27) Its use in combination with irinotecan confers a prognostic benefit for patients with SCC. 11) However, hematological adverse events are problematic in nedaplatin-based chemotherapy.…”

“…11) However, hematological adverse events are problematic in nedaplatin-based chemotherapy. 10) Because SCC frequently occurs in smoking elderly men who might have complicating respiratory disorders, vascular disorders, or other cancers, 28) these toxicities might negatively influence patient prognosis.…”

“…5,6) Platinum-based doublet chemotherapy is commonly used for recurrent SCC, while various types of therapy, including molecular targeted drugs, are used for recurrent pulmonary adenocarcinoma. [7][8][9][10][11] Whether the favorable prognosis of patients with resectable advanced SCC is due to the less aggressive nature of the SCC tumor or the therapeutic effect of the chemotherapy on SCC remains unclear.…”